SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Bakoush Omran)
 

Sökning: WFRF:(Bakoush Omran) > (2010-2014) > Different fractions...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007796naa a2200613 4500
001oai:DiVA.org:liu-79630
003SwePub
008120813s2012 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:6703c645-3d73-4248-aad1-07a30b710d6b
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-796302 URI
0247 a https://doi.org/10.1016/j.bbagen.2012.01.0072 DOI
0247 a https://lup.lub.lu.se/record/23359532 URI
040 a (SwePub)liud (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Carlsson, Michaelu Lund University,Lunds universitet,Avdelningen för mikrobiologi, immunologi och glykobiologi - MIG,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Microbiology, Immunology and Glycobiology - MIG,Department of Laboratory Medicine,Faculty of Medicine,Lund University, Sweden4 aut0 (Swepub:lu)med-mcc
2451 0a Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease
264 1b Elsevier,c 2012
338 a electronic2 rdacarrier
500 a Funding Agencies|Swedish Research Council (Vetenskapsradet)||Region Skane||Swedish Cancer Society||Lund University Hospital Foundation||Swedish Research Council|2008-3356|Swedish Foundation for Swedish Research|FFL4|Crafoord Foundation||Swedish Healthcare System||
520 a Background: Changes in glycosylation of serum proteins are common, and various glycoforms are being explored as biomarkers in cancer and inflammation. We recently showed that glycoforms detected by endogenous galectins not only provide potential biomarkers, but also have different functions when they encounter galectins in tissue cells. Now we have explored the use of a combination of two galectins with different specificities, to further increase biomarker sensitivity and specificity. less thanbrgreater than less thanbrgreater thanMethods: Sera from 14 women with metastatic breast cancer, 12 healthy controls, 14 patients with IgA-nephritis (IgAN), and 12 patients with other glomerulonephritis were fractionated by affinity chromatography on immobilized human galectin-1 or galectin-8N, and the protein amounts of the bound and unbound fractions for each galectin were determined. less thanbrgreater than less thanbrgreater thanResults: Each galectin bound largely different fractions of the serum glycoproteins, including different glycoforms of haptoglobin. In the cancer sera, the level of galectin-1 bound glycoproteins was higher and galectin-8N bound glycoproteins lower compared to the other patients groups, whereas in IgAN sera the level of galectin-8N bound glycoproteins were higher. less thanbrgreater than less thanbrgreater thanConclusion: The ratio of galectin-1 bound/galectin-8N bound glycoproteins showed high discriminatory power between cancer patients and healthy, with AUC of 0.98 in ROC analysis, and thus provides an interesting novel cancer biomarker candidate. less thanbrgreater than less thanbrgreater thanGeneral significance: The galectin-binding ability of a glycoprotein is not only a promising biomarker candidate but may also have a specific function when the glycoprotein encounters the galectin in tissue cells, and thus be related to the pathophysiological state of the patient. This article is part of a Special Issue entitled Glycoproteomics.
650 7a NATURVETENSKAPx Biologi0 (SwePub)1062 hsv//swe
650 7a NATURAL SCIENCESx Biological Sciences0 (SwePub)1062 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Galectin-1
653 a Galectin-8
653 a Biomarkers
653 a Cancer
653 a IgA-nephropathy
653 a Serum glycoprotein
653 a MEDICINE
653 a MEDICIN
7001 a Balog, Crina I Au Leiden University, Netherlands,Leiden University Medical Centre4 aut
7001 a Kilsgård, Olau Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,Infection Medicine Proteomics,Forskargrupper vid Lunds universitet,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,Lund University Research Groups,Lund University, Sweden4 aut0 (Swepub:lu)immu-oki
7001 a Hellmark, Thomasu Lund University,Lunds universitet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Autoimmunitet och njursjukdomar,Forskargrupper vid Lunds universitet,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Autoimmunity and kidney diseases,Lund University Research Groups,University of Lund Hospital, Sweden4 aut0 (Swepub:lu)njur-the
7001 a Bakoush, Omranu Lund University,Lunds universitet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Lund Hospital, Sweden4 aut0 (Swepub:lu)njur-oba
7001 a Segelmark, Mårtenu Lund University,Lunds universitet,Linköpings universitet,Farmakologi,Hälsouniversitetet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)njur-mse
7001 a Fernö, Mårtenu Linköping University,Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Lund Hospital, Sweden4 aut0 (Swepub:lu)onk-mfe
7001 a Olsson, Håkanu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Lund Hospital, Sweden4 aut0 (Swepub:lu)onk-hol
7001 a Malmström, Johanu Lund University,Lunds universitet,Infection Medicine Proteomics,Forskargrupper vid Lunds universitet,Lund University Research Groups,Lund University, Sweden4 aut0 (Swepub:lu)medk-jma
7001 a Wuhrer, Manfredu Leiden University, Netherlands,Leiden University Medical Centre4 aut
7001 a Leffler, Hakonu Lund University,Lunds universitet,Avdelningen för mikrobiologi, immunologi och glykobiologi - MIG,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Microbiology, Immunology and Glycobiology - MIG,Department of Laboratory Medicine,Faculty of Medicine,Lund University, Sweden Skåne University Hospital, Sweden4 aut0 (Swepub:lu)mmb-hle
7102 a Avdelningen för mikrobiologi, immunologi och glykobiologi - MIGb Institutionen för laboratoriemedicin4 org
7730 t Biochimica et Biophysica Acta - General Subjectsd : Elsevierg 1820:9, s. 1366-1372q 1820:9<1366-1372x 0304-4165x 1872-8006x 0006-3002
8564 u https://liu.diva-portal.org/smash/get/diva2:543981/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint
8564 u http://liu.diva-portal.org/smash/get/diva2:543981/FULLTEXT01
8564 u http://www.ncbi.nlm.nih.gov/pubmed/22285770?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1016/j.bbagen.2012.01.007y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-79630
8564 8u https://doi.org/10.1016/j.bbagen.2012.01.007
8564 8u https://lup.lub.lu.se/record/2335953

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy